Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET

Company Participants

Keri Mattox - Chief Communications and Administration Officer
Ivan Tornos - President and CEO
Suky Upadhyay - Executive Vice President, Finance, Operations and Supply Chain, and CFO

Conference Call Participants

Travis Steed - Bank of America
Steve Lichtman - Oppenheimer & Company
Vik Chopra - Wells Fargo
Rick Wise - Stifel
Imron Zafar - Deutsche Bank
Caitlin Cronin - Canaccord Genuity
Mike Matson - Needham & Company
Robbie Marcus - JPMorgan
Chris Pasquale - Nephron
Shagun Singh - RBC

Operator

Good morning, ladies and gentlemen. And welcome to the Zimmer Biomet First Quarter 2024 Earnings Conference Call. [Operator Instructions]

As a reminder, this conference is being recorded today, May 2, 2024. Following today’s presentation, there will be a question-and-answer session. At this time, all participants are in a listen-only mode. [Operator Instructions]

I would now like to turn the conference over to Keri Mattox, Chief Communications and Administration Officer. Please go ahead.

Keri Mattox

Thank you, Operator, and good morning, everyone. Welcome to Zimmer Biomet first quarter 2024 earnings conference call. Joining me today are Ivan Tornos, our President and CEO; and CFO and EVP, Finance, Operations, and Supply Chain, Suky Upadhyay.

Before we get started, I’d like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties.

Please note we assume no obligation to update these forward-looking statements, even if the actual results or future expectations change materially. Please refer to our SEC filings for a detailed discussion of these risks and uncertainties, in addition to the inherent limitations of such forward-looking statements.

Additionally, the discussions on this call will include certain non-GAAP financial measures, some of which are forward-looking non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures and an explanation of our basis for calculating these measures is included within our Q1 earnings release, which can be found on our website, zimmerbiomet.com.

With that, I’ll turn the call over to Ivan. Ivan?

Ivan Tornos

Thank you, Keri, and thank you everyone for joining the call here this morning. I’d like to start today the way that I typically do, by taking a moment to recognize and to show my gratitude to the 18,000 Zimmer Biomet team members across the globe who each and every day work relentlessly in driving our mission forward.